医疗技术公司TransMedics Group Inc.(TMDX.US)周五盘后股价大跌近25%,引发了市场的广泛关注。公司公布的2024年第三季度财报数据显示,营收和净利润双双低于市场预期,令投资者对公司的增长前景失去信心。
具体来看,第三季度营收为1.088亿美元,低于分析师平均预期的1.15亿美元。净利润为每股12美分,也未达到预期的29美分。虽然公司维持了全年营收指引在4.25亿至4.45亿美元之间,但投资人显然对其业绩增长表示失望。
TransMedics Group是一家从事医疗器械的公司,专门为终末期器官衰竭患者提供移植治疗。公司本季度业绩未达预期,暴露出在某些领域可能面临增长挑战,这也令股价在盘后大幅下挫近25%。股票大跌反映了市场对公司前景的担忧情绪。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.